Zoltán Kis

Dr. Zoltán Kis serves as a Senior Lecturer (Associate Professor) in the School of Chemical, Materials and Biological Engineering at The University of Sheffield and holds an Honorary Lecturer position at Imperial College London's Department of Chemical Engineering. His research focuses on innovating disease-agnostic RNA vaccine and therapeutics manufacturing platforms through process digitalization and intensification.

Dr. Kis earned his Ph.D. in Bioengineering from Imperial College London, complemented by an M.Sc. in Applied Biotechnology and a B.Eng. in Chemical with Biochemical Engineering. His interdisciplinary training bridges chemical engineering, biotechnology, and bioengineering disciplines.

His research integrates experimental and computational methodologies to revolutionize mRNA production:

• Development of continuous enzymatic synthesis, purification, and LNP formulation processes
• Process intensification through novel unit operations and equipment design
• Digital twin deployment for real-time monitoring and control
• Techno-economic modeling to reduce production costs
• Quality by Digital Design framework implementation for regulatory compliance

Analysis of recent publications reveals dominant trends in continuous bioprocessing and digital transformation of mRNA manufacturing. Key subfields include oligo-dT chromatography optimization, tangential flow filtration for mRNA purification, and digital twin applications for process control, with strong emphasis on pandemic-response capabilities and cost reduction strategies.

Dr. Kis actively supervises PhD students in mRNA bioprocessing and teaches Biopharmaceutical Manufacturing (CPE336/CPE6043) and Introduction to Bioengineering (BIE103). His industry engagement includes advisory roles on Sanofi's mRNA CMC Board and Pfizer's mRNA Technology Advisory Board.

He leads the RNA Manufacturing Innovation Team and has secured substantial research funding, including:

• £3.7 million CEPI grant for RNAbox platform (2024-2027)
• £7.6 million UK-SEA Vaccine Manufacturing Hub (2023-2028)
• £2 million Innovate UK project for automated RNA platform (2023-2025)
• Multi-million USD Wellcome Leap R3 grant for distributed RNA production

His work demonstrates significant impact through industry partnerships, policy advisory roles including WHO mRNA Technology Transfer Hub consultancy, and leadership in advancing global vaccine manufacturing capabilities.